Trial Profile

An Open Label Phase II Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipifarnib (Primary)
Indications Carcinoma; Urogenital cancer
Focus Therapeutic Use

Most Recent Events

06 Mar 2022 Planned End Date changed from 1 Mar 2020 to 1 Jun 2022.
06 Mar 2022 Planned primary completion date changed from 1 Dec 2019 to 1 Mar 2022.
07 Jul 2020 Status changed to active, no longer recruiting as per results published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com